» Articles » PMID: 37949355

IL-6/JAK2-dependent G6PD Phosphorylation Promotes Nucleotide Synthesis and Supports Tumor Growth

Overview
Journal Mol Metab
Specialty Cell Biology
Date 2023 Nov 10
PMID 37949355
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Tumor cells hijack inflammatory mechanisms to promote their own growth. IL-6 is one of the major cytokines, and is frequently upregulated in tumors. The pentose phosphate pathway (PPP) generates the indispensable building blocks to produce various nucleotides. Here we aimed to determine whether and how PPP is timely tuned in response to IL-6 to support tumor growth.

Methods: Protein expression was examined by immunoblot. Protein interaction was examined by immunoprecipitation. Tumor cell proliferation in in vitro culture was examined by BrdU assay and colony formation assay. Tumor cell proliferation in mouse xenograft model was examined by Ki-67 staining.

Results: Here we show that the metabolic flux of PPP and enzymatic activity of glucose-6-phosphate dehydrogenase (G6PD) is rapidly induced under IL-6 treatment, without obvious changes in G6PD expression level. Mechanistically, Janus kinase 2 (JAK2) phosphorylates G6PD Y437 under IL-6 treatment, which accentuates G6PD enzymatic activity by promoting G6PD binding with its substrate G6P. Further, JAK2-dependent G6PD Y437 phosphorylation is required for IL-6-induced nucleotide biosynthesis and tumor cell proliferation, and is associated with the progression of oral squamous cell carcinoma.

Conclusions: Our findings report a new mechanism implicated in the crosstalk between tumor cells and inflammatory microenvironment, by which JAK2-dependent activation of G6PD governs nucleotide synthesis to support tumor cell proliferation, thereby highlighting its value as a potential anti-tumor target.

Citing Articles

The Role of Glucose-6-Phosphate Dehydrogenase in Skin Cancer Metabolism: A Paradigm Shift in Treatment Approaches.

Abdullah A, Kumbrink J, Liokatis P, Mock A, Abdullah A, Dewenter I Cancers (Basel). 2025; 17(1.

PMID: 39796677 PMC: 11718909. DOI: 10.3390/cancers17010048.


Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy.

Gan M, Liu N, Li W, Chen M, Bai Z, Liu D Mol Cancer. 2024; 23(1):273.

PMID: 39696340 PMC: 11657557. DOI: 10.1186/s12943-024-02193-7.

References
1.
OLeary E, Mazurkiewicz-Munoz A, Argetsinger L, Maures T, Huynh H, Carter-Su C . Identification of steroid-sensitive gene-1/Ccdc80 as a JAK2-binding protein. Mol Endocrinol. 2013; 27(4):619-34. PMC: 3607695. DOI: 10.1210/me.2011-1275. View

2.
Wei X, Kixmoeller K, Baltrusaitis E, Yang X, Marmorstein R . Allosteric role of a structural NADP molecule in glucose-6-phosphate dehydrogenase activity. Proc Natl Acad Sci U S A. 2022; 119(29):e2119695119. PMC: 9303983. DOI: 10.1073/pnas.2119695119. View

3.
Zanoni D, Montero P, Migliacci J, Shah J, Wong R, Ganly I . Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. 2019; 90:115-121. PMC: 6417804. DOI: 10.1016/j.oraloncology.2019.02.001. View

4.
Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

5.
Greten F, Grivennikov S . Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1):27-41. PMC: 6831096. DOI: 10.1016/j.immuni.2019.06.025. View